Keyphrases
Abiraterone
17%
American Society of Hematology
21%
Anticoagulants
10%
Anticoagulation
32%
Apixaban
20%
Assessment Development
9%
Bleeding
18%
Body Mass Index
10%
Cancer Patients
9%
Cancer-associated Thrombosis
8%
Cancer-associated Venous Thromboembolism
16%
Chemotherapy
12%
Comorbid Diseases
9%
Comparative Effectiveness
9%
Confidence Interval
21%
Coronavirus Disease (COVID)
10%
COVID-19
12%
Diffuse Large B-cell Lymphoma (DLBCL)
19%
Direct Oral Anticoagulants
23%
Dose Reduction
11%
Enzalutamide
17%
Evaluation Assessment
9%
Frailty
9%
Grading of Recommendations
9%
Hematological Malignancies
9%
Hemostasis
19%
High Risk
10%
Hospitalization
9%
In Cancer
18%
Living Guidelines
17%
Major Bleeding
9%
Malignancy
16%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
13%
Monoclonal Gammopathy of Undetermined Significance
12%
Multiple Myeloma
67%
Overall Survival
10%
Patients with Cancer
14%
Patients with COVID-19
18%
Reduced Dose
8%
Retrospective Cohort Study
13%
Secondary Prevention
9%
Statins
8%
Thromboprophylaxis
30%
Thrombosis
24%
United States Veterans
21%
US Veterans
8%
Venous Thromboembolism
80%
Venous Thromboembolism Risk
11%
Venous Thromboembolism Treatment
9%
Warfarin
11%
Medicine and Dentistry
Acute Disease
6%
Anticoagulant Therapy
6%
Anticoagulation
33%
Antithrombotic
9%
Apixaban
17%
Bleeding
22%
Blood Stasis
19%
Body Mass Index
6%
Cancer
15%
Cancer Treatment
10%
CHOP
8%
Clinician
18%
COVID-19
34%
Critical Illness
7%
Dexamethasone
5%
Diffuse Large B-Cell Lymphoma
13%
Direct Oral Anticoagulant
18%
Diseases
7%
Drug Dose Reduction
9%
Hazard Ratio
9%
Health Outcomes
5%
Hematologic Malignancy
14%
Hematology
21%
International Classification of Diseases
5%
Lenalidomide
5%
Low Molecular Weight Heparin
5%
Major Bleeding
9%
Malignant Neoplasm
26%
Monoclonal Gammopathy of Undetermined Significance
8%
Multiple Myeloma
50%
Myeloma
8%
Odds Ratio
10%
Overall Survival
6%
Pancreas Adenocarcinoma
5%
Pancreas Cancer
8%
Phlebothrombosis
5%
Randomized Clinical Trial
5%
Randomized Controlled Trial
6%
Retrospective Cohort Study
9%
Risk Stratification
5%
Rivaroxaban
5%
Sarcopenia
8%
Secondary Prevention
9%
Thrombocytopenia
8%
Thromboprophylaxis
30%
Thrombosis
38%
Venous Thromboembolism
100%
Pharmacology, Toxicology and Pharmaceutical Science
Abiraterone
17%
Apixaban
10%
Bleeding
17%
Chemotherapy
18%
Cohort Study
14%
Dexamethasone
5%
Diffuse Large B Cell Lymphoma
14%
Direct Oral Anticoagulant
13%
Diseases
13%
Enzalutamide
17%
Frailty
8%
Hematologic Malignancy
9%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
8%
Lenalidomide
5%
Malignant Neoplasm
19%
Monoclonal Immunoglobulinemia
12%
Multiple Myeloma
50%
Myeloma
8%
Overall Survival
7%
Prostate Cancer
13%
Thrombosis
23%
Venous Thromboembolism
52%
Warfarin
13%